gastroenterology Archives -

Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up

Takeda spinout Phathom claims its first FDA approvals

https://pharmaphorum.com/news/takeda-spinout-phathom-claims-its-first-fda-approvals/

Data sets up ulcerative colitis expansion for BMS’ MS drug Zeposia

Phil Taylor Bristol-Myers Squibb, gastroenterology, immunology, Ozanimod, ulcerative colitis, Zeposia 0 Comment

Bristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis –

Data sets up ulcerative colitis expansion for BMS’ MS drug Zeposia

https://pharmaphorum.com/news/data-sets-up-ulcerative-colitis-expansion-for-bms-ms-drug-zeposia/

A healthy discussion on funding tomorrow’s treatments

News/ News/ Sales and Marketing

Despite biosims, ulcerative colitis drugs still cost too much; ICER

Phil Taylor AbbVie, gastroenterology, Humira, inflammatory bowel disease, Johnson & Johnson, Merck & Co, Pfizer, Takeda, ulcerative colitis 0 Comment

None of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough

Despite biosims, ulcerative colitis drugs still cost too much; ICER

https://pharmaphorum.com/news/despite-biosims-ulcerative-colitis-drugs-still-cost-too-much-icer/

News

Takeda posts surprise profit a year after Shire mega-merger

Richard Staines gastroenterology, M&A, neurology, Oncology, Rare diseases, Shire, Takeda 0 Comment

Japan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year

Takeda posts surprise profit a year after Shire mega-merger

https://pharmaphorum.com/news/takeda-posts-surprise-profit-a-year-after-shire-mega-merger/

News/ News/ R&D

Ferring’s gut microbiome drug clears phase 3 trial in C. diff

Phil Taylor C. diff infections, clinical trial, Ferring, gastroenterology, infectious disease, microbiome, Rebiotix 0 Comment

Ferring Pharma has reported what it says is the first positive phase 3 trial of a microbiome therapy

Ferring’s gut microbiome drug clears phase 3 trial in C. diff

https://pharmaphorum.com/news/ferrings-gut-microbiome-drug-clears-phase-3-trial-in-c-diff/

Market Access/ News/ News/ News/ News/ Patients/ Sales and Marketing

FDA says all ranitidine drugs should be recalled on safety concerns

Phil Taylor gastroenterology, regulation, safety 0 Comment

The FDA has asked drugmakers to pull all prescription and over-the-counter products based on ranitidine off the market

FDA says all ranitidine drugs should be recalled on safety concerns

https://pharmaphorum.com/news/fda-says-all-ranitidine-drugs-should-be-recalled-on-safety-concerns/

News/ News/ R&D/ Top stories

Takeda buys US biotech PvP Biologics for $330 million

Richard Staines coeliac disease, gastroenterology, M&A, R&D, Takeda 0 Comment

Takeda has bought US biotech PvP Biologics for $330 million, adding a potential new form of therapy for

Takeda buys US biotech PvP Biologics for $330 million

https://pharmaphorum.com/news/takeda-buys-us-biotech-pvp-biologics-for-330-million/

News/ News/ R&D

Takeda buys coeliac drug licence from COUR Pharmaceuticals

Richard Staines coeliac disease, gastroenterology, Takeda 0 Comment

Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced

Takeda buys coeliac drug licence from COUR Pharmaceuticals

https://pharmaphorum.com/news/takeda-buys-coeliac-drug-licence-from-cour-pharmaceuticals/

News

AZ sells rights to gastro drug Losec to Cheplapharm in $309m deal

Richard Staines AstraZeneca, Cheplapharm, gastroenterology 0 Comment

AstraZeneca has agreed to sell most global commercial rights to its gastro drug Losec (omeprazole) and associated brands

AZ sells rights to gastro drug Losec to Cheplapharm in $309m deal

https://pharmaphorum.com/news/az-sells-rights-to-gastro-drug-losec-to-cheplapharm/

Trending

gastroenterology

Login